Non-enteric Infections, Antibiotic Use, and Risk of Development of Functional Gastrointestinal Disorders

Overview

Journal Neurogastroenterol Motil

Specialties Gastroenterology
Neurology

Date 2015 Aug 26

PMID 26303310

Citations 24

Authors

H Paula

M Grover

S L Halder

G R Locke 3rd

C D Schleck

A R Zinsmeister

N J Talley

Affiliations

Soon will be listed here.

Abstract

Background: Gastrointestinal infections are risk factors for irritable bowel syndrome (IBS) and functional dyspepsia (FD). We investigated whether non-enteric infections and antibiotic exposure are also associated with the development of functional gastrointestinal disorders (FGIDs).

Methods: In a nested case-control study, random samples of Olmsted County, MN, were mailed valid self-report questionnaires from 1988 through 1994, and then follow-up questionnaires from 1995 through 2003. Survey responders who did not report any FGID symptoms at baseline, but then reported such symptoms in at least one subsequent survey, were classified as new-onset cases. Age-matched controls were individuals who did not have symptoms at either the initial or subsequent surveys.

Key Results: The overall response rate was 78% to the initial survey and 52% to the follow-up survey. Based on the responses, 316 participants had a new onset of an FGID (43 IBS constipation, 95 IBS diarrhea, 25 IBS mixed, and 153 other FGIDs, including FD) and 250 did not (controls). Around 76% (241/316) of cases reported a non-enteric infection vs 66% (166/250) of the controls. The frequency of enteric infections was similar between the two groups. Of the new FGID cases, 83% had a non-enteric infection that was treated with antibiotic. In a logistic regression model, treatment with antibiotics for a non-gastrointestinal infection was associated with the development of an FGID (odds ratio = 1.90; 95% CI: 1.21-2.98; p = 0.005), after adjusting for age and sex.

Conclusions & Inferences: Based on a case-control study, treatment of a non-gastrointestinal infection with antibiotics appears to be a risk factor for development of an FGID.

Citing Articles

Modulating the gut microenvironment as a treatment strategy for irritable bowel syndrome: a narrative review.

Iribarren C, Maasfeh L, Ohman L, Simren M Gut Microbiome (Camb). 2024; 3:e7.

PMID: 39295774 PMC: 11406401. DOI: 10.1017/gmb.2022.6.

The gut microbiome in disorders of gut-brain interaction.

Kraimi N, Ross T, Pujo J, Palma G Gut Microbes. 2024; 16(1):2360233.

PMID: 38949979 PMC: 11218806. DOI: 10.1080/19490976.2024.2360233.

Antibiotics and Probiotics for Irritable Bowel Syndrome.

Goodoory V, Ford A Drugs. 2023; 83(8):687-699.

PMID: 37184752 DOI: 10.1007/s40265-023-01871-y.

The Prevalence, Humanistic Burden, and Health Care Impact of Irritable Bowel Syndrome Among United States Veterans.

Shin A, Xu H, Imperiale T Clin Gastroenterol Hepatol. 2022; 21(4):1061-1069.e1.

PMID: 35964894 PMC: 9918609. DOI: 10.1016/j.cgh.2022.08.005.

Metabolomics: The Key to Unraveling the Role of the Microbiome in Visceral Pain Neurotransmission.

Shute A, Bihan D, Lewis I, Nasser Y Front Neurosci. 2022; 16:917197.

PMID: 35812241 PMC: 9260117. DOI: 10.3389/fnins.2022.917197.

References

McKeown E, Parry S, Stansfield R, Barton J, Welfare M . Postinfectious irritable bowel syndrome may occur after non-gastrointestinal and intestinal infection. Neurogastroenterol Motil. 2006; 18(9):839-43. DOI: 10.1111/j.1365-2982.2006.00821.x. View

Ji S, Park H, Lee D, Song Y, Choi J, Lee S . Post-infectious irritable bowel syndrome in patients with Shigella infection. J Gastroenterol Hepatol. 2005; 20(3):381-6. DOI: 10.1111/j.1440-1746.2005.03574.x. View

Mearin F, Perez-Oliveras M, Perello A, Vinyet J, Ibanez A, Coderch J . Dyspepsia and irritable bowel syndrome after a Salmonella gastroenteritis outbreak: one-year follow-up cohort study. Gastroenterology. 2005; 129(1):98-104. DOI: 10.1053/j.gastro.2005.04.012. View

Sharara A, Aoun E, Abdul-Baki H, Mounzer R, Sidani S, ElHajj I . A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence. Am J Gastroenterol. 2006; 101(2):326-33. DOI: 10.1111/j.1572-0241.2006.00458.x. View

Quigley E . Germs, gas and the gut; the evolving role of the enteric flora in IBS. Am J Gastroenterol. 2006; 101(2):334-5. DOI: 10.1111/j.1572-0241.2006.00445.x. View

Drossman D . The functional gastrointestinal disorders and the Rome III process. Gastroenterology. 2006; 130(5):1377-90. DOI: 10.1053/j.gastro.2006.03.008. View

Gwee K, Chua A . Functional dyspepsia and irritable bowel syndrome, are they different entities and does it matter?. World J Gastroenterol. 2006; 12(17):2708-12. PMC: 4130979. DOI: 10.3748/wjg.v12.i17.2708. View

Borgaonkar M, Ford D, Marshall J, Churchill E, Collins S . The incidence of irritable bowel syndrome among community subjects with previous acute enteric infection. Dig Dis Sci. 2006; 51(5):1026-32. DOI: 10.1007/s10620-006-9348-1. View

Gwee K, GRAHAM J, McKendrick M, Collins S, Marshall J, Walters S . Psychometric scores and persistence of irritable bowel after infectious diarrhoea. Lancet. 1996; 347(8995):150-3. DOI: 10.1016/s0140-6736(96)90341-4. View

10.

Neal K, Hebden J, Spiller R . Prevalence of gastrointestinal symptoms six months after bacterial gastroenteritis and risk factors for development of the irritable bowel syndrome: postal survey of patients. BMJ. 1997; 314(7083):779-82. PMC: 2126206. DOI: 10.1136/bmj.314.7083.779. View

11.

Gwee K, Leong Y, Graham C, McKendrick M, Collins S, Walters S . The role of psychological and biological factors in postinfective gut dysfunction. Gut. 1999; 44(3):400-6. PMC: 1727402. DOI: 10.1136/gut.44.3.400. View

12.

Rodriguez L, Ruigomez A . Increased risk of irritable bowel syndrome after bacterial gastroenteritis: cohort study. BMJ. 1999; 318(7183):565-6. PMC: 27756. DOI: 10.1136/bmj.318.7183.565. View

13.

Talley N, Stanghellini V, Heading R, Koch K, Malagelada J, Tytgat G . Functional gastroduodenal disorders. Gut. 1999; 45 Suppl 2:II37-42. PMC: 1766695. DOI: 10.1136/gut.45.2008.ii37. View

14.

Thompson W, Longstreth G, Drossman D, Heaton K, Irvine E, Muller-Lissner S . Functional bowel disorders and functional abdominal pain. Gut. 1999; 45 Suppl 2:II43-7. PMC: 1766683. DOI: 10.1136/gut.45.2008.ii43. View

15.

Rhodes D, Wallace M . Post-infectious irritable bowel syndrome. Curr Gastroenterol Rep. 2006; 8(4):327-32. DOI: 10.1007/s11894-006-0054-0. View

16.

Jalanka-Tuovinen J, Salojarvi J, Salonen A, Immonen O, Garsed K, Kelly F . Faecal microbiota composition and host-microbe cross-talk following gastroenteritis and in postinfectious irritable bowel syndrome. Gut. 2013; 63(11):1737-45. DOI: 10.1136/gutjnl-2013-305994. View

17.

Uusijarvi A, Bergstrom A, Simren M, Ludvigsson J, Kull I, Wickman M . Use of antibiotics in infancy and childhood and risk of recurrent abdominal pain--a Swedish birth cohort study. Neurogastroenterol Motil. 2014; 26(6):841-50. DOI: 10.1111/nmo.12340. View

18.

Grover M, Camilleri M, Smith K, Linden D, Farrugia G . On the fiftieth anniversary. Postinfectious irritable bowel syndrome: mechanisms related to pathogens. Neurogastroenterol Motil. 2014; 26(2):156-67. DOI: 10.1111/nmo.12304. View

19.

Porter C, Faix D, Shiau D, Espiritu J, Espinosa B, Riddle M . Postinfectious gastrointestinal disorders following norovirus outbreaks. Clin Infect Dis. 2012; 55(7):915-22. DOI: 10.1093/cid/cis576. View

20.

Zanini B, Ricci C, Bandera F, Caselani F, Magni A, Laronga A . Incidence of post-infectious irritable bowel syndrome and functional intestinal disorders following a water-borne viral gastroenteritis outbreak. Am J Gastroenterol. 2012; 107(6):891-9. DOI: 10.1038/ajg.2012.102. View